Physician profile

Leera Patel

Endocrinology, Diabetes & Metabolism · Lexington, KY

NPI 1619932803

$33,791.77

in general payments reported to CMS, 2019-2025

19 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $32,482.38 2019
Novo Nordisk INC $198.26 2019-2021
Shire North American Group INC $182.71 2019
Sanofi-Aventis U.S. LLC $164.55 2019
Abbvie INC. $154.72 2019
Amgen INC. $120.83 2019
Corcept Therapeutics $79.63 2019
Boehringer Ingelheim Pharmaceuticals, INC. $65.58 2019
Merck Sharp & Dohme LLC $64.48 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $56.65 2019
Dexcom, INC. $45.21 2019
Janssen Pharmaceuticals, INC $43.77 2019
Insulet Corporation $30.78 2019-2020
Amarin Pharma, INC. $25.99 2019
Abbott Laboratories $17.40 2019
Show all 19 companies
CompanyGeneral paymentsYearsTop products
Amneal Pharmaceuticals LLC $17.37 2019
Mannkind Corporation $14.32 2019
Ibsa Pharma INC. $14.14 2019
Senseonics, Incorporated $13.00 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Leera Patel

$33,791.77

in general payments reported 2019-2025

Years
2019-2021
Top company
Lilly USA, LLC

https://glasscript.com/doctor/118396/leera-patel

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.